Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionRWJ - Invesco S&P SmallCap 600 Revenue ETF
Latest Disclosed Ownership28,382 shares
Latest Disclosed Value $ 655,056
RWJ - Invesco S&P SmallCap 600 Revenue ETF reports 10.07% decrease in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On April 28, 2026 - RWJ - Invesco S&P SmallCap 600 Revenue ETF filed a NPORT-P form disclosing ownership of 28,382 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $655,057 USD as of February 28, 2026. The entity filed a previous NPORT-P on January 28, 2026 disclosing 31,560 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of -10.07% during the quarter. The current value of the position is $893,749 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-28 2026-02-28 NP Catalyst Pharmaceuticals EC US14888U1016 28,382 -3,178 -10.07 655 -11.25 0.0385
2026-01-28 2025-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 31,560 9,396 42.39 739 61.84 0.0476
2025-10-28 2025-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 22,164 -2,799 -11.21 456 -26.81 0.0286
2025-07-28 2025-05-31 NP Catalyst Pharmaceuticals EC US14888U1016 24,963 -7,639 -23.43 623 -16.49 0.0424
2025-04-25 2025-02-28 NP Catalyst Pharmaceuticals EC US14888U1016 32,602 6,163 23.31 746 27.96 0.0431
2025-01-29 2024-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 26,439 -2,838 -9.69 584 -1.52 0.0318
2024-10-28 2024-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 29,277 1,348 4.83 593 31.26 0.0370
2024-07-29 2024-05-31 NP Catalyst Pharmaceuticals EC US14888U1016 27,929 1,356 5.10 452 6.12 0.0301
2024-04-25 2024-02-29 NP Catalyst Pharmaceuticals EC US14888U1016 26,573 556 2.14 426 13.33 0.0285
2024-01-29 2023-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 26,017 1,198 4.83 375 7.76 0.0283
2023-10-30 2023-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 24,819 10,607 74.63 348 112.20 0.0254
2023-07-28 2023-05-31 NP Catalyst Pharmaceuticals EC US14888U1016 14,212 2,146 17.79 164 -10.87 0.0143
2023-05-01 2023-02-28 NP Catalyst Pharmaceuticals EC US14888U1016 12,066 12,066 184 0.0153
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.